Pharma News India Monthly – September 2026

The Indian pharmaceutical industry navigated a month of remarkable strategic investment, global export expansion, and a growing raw material cost crisis during September 2026. From the approval of ₹1,600 crore in innovation funding to a massive international exhibition generating billions in business discussions, the month demonstrated India's growing stature as a global pharmaceutical powerhouse. However, beneath these achievements lies a deepening concern: the relentless rise in raw material and packaging material prices is squeezing pharmaceutical manufacturers, particularly MSMEs, and if costs cannot be recovered, the ultimate burden will fall on patients through higher medicine prices.

This comprehensive edition of Pharma News India Monthly covers all verified developments shaping the industry from 01 September 2026 to 30 September 2026. The month was defined by a decisive push toward research and innovation, with the government approving major funding for pharmaceutical and medical technology projects. Simultaneously, Indian companies continued to expand their global footprint through strategic export diversification, while regulatory authorities took firm action against quality violations and counterfeit products.

Yet the most pressing challenge facing the industry today is the unprecedented surge in input costs. Prices of active pharmaceutical ingredients, solvents, excipients, and packaging materials have skyrocketed, in some cases by 200-300 percent, driven by geopolitical disruptions and supply chain bottlenecks. The pharmaceutical industry has been absorbing these costs internally, but margins are under severe strain. Industry bodies have warned that if prices cannot be recovered, the eventual outcome will be higher medicine prices and a negative impact on public health. Government support is urgently needed to protect both industry viability and patient affordability.

Whether you are a healthcare professional tracking industry trends, a pharmaceutical company monitoring regulatory changes, or an investor evaluating growth opportunities, this detailed monthly roundup delivers the essential intelligence required to navigate India's rapidly evolving pharmaceutical landscape.

Raw Material and Packaging Material Price Surge Threatens Pharma Industry Viability

Publication Date: Throughout September 2026

The Indian pharmaceutical industry is facing its most severe input cost crisis in recent memory, with prices of critical raw materials and packaging materials surging dramatically throughout 2026. Paracetamol, one of the most widely used medicines, has seen its active pharmaceutical ingredient price more than double from approximately ₹220-240 per kg to ₹550-650 per kg. The situation has become so severe that the Himachal Drug Manufacturers Association reported input costs surging by 200-300 percent across APIs, solvents, excipients, and packaging materials.

The crisis stems from multiple factors. Geopolitical tensions in West Asia have disrupted supply chains for petrochemical-based raw materials, solvents, and intermediates. Methanol, propylene, and ammonia—all critical feedstocks for drug manufacturing—have been affected by the conflict. Freight rates on affected routes have surged multiple-fold, while war-risk insurance premiums and prolonged shipping timelines have added further stress.

Packaging materials have not been spared. Petroleum-based materials such as PET bottles, aluminium caps, foil, and PVC have seen steep increases of 80-100 percent. PVC, commonly used for blister packs, has risen from ₹130 per kg to ₹190 per kg. Aluminium foil prices have climbed from ₹400 per kg to ₹600 per kg, while premium Alu-Alu packaging has increased from ₹360 per kg to ₹560 per kg.

The impact on pharmaceutical manufacturers, particularly MSMEs, has been devastating. Smaller firms operate with limited inventory buffers of around three to six weeks due to working capital constraints and have limited ability to hedge costs or pass them on to buyers. The Himachal Drug Manufacturers Association, representing over 500 pharmaceutical manufacturing units, has urged the government to impose emergency price ceilings and form a crisis task force, warning that the situation threatens MSME survival and essential medicine supply.

Industry leaders have warned that if input costs continue to rise and manufacturers cannot recover these costs, the inevitable outcome will be higher prices for medicines. The pharmaceutical industry is seeking government support through measures such as temporary price relaxations, freight subsidies, GST relief on key inputs, and faster processing of refunds to maintain both industry viability and patient access to affordable medicines.

Why It Matters: The pharmaceutical industry's ability to maintain affordable medicine prices is under severe threat from unprecedented raw material and packaging cost increases.

Impact on Patients: If costs cannot be absorbed or recovered, patients will face higher medicine prices, potentially affecting healthcare affordability and access.

Impact on Pharmaceutical Companies: MSMEs face the greatest risk, with many operating on thin margins and limited capacity to absorb cost increases.

Impact on Healthcare: The viability of essential medicine supply is at risk, potentially leading to shortages of critical drugs.

iPHEX 2026 Concludes with $4.5–5 Billion in Potential Business Discussions

Publication Date: 11 September 2026

The 12th edition of the International Exhibition on Pharma and Healthcare, organized by the Pharmaceuticals Export Promotion Council of India, concluded at Bharat Mandapam with potential business discussions estimated at $4.5–5 billion. The event, held from September 7 to 9, recorded 468 buyers, 405 sellers, and 8,504 meetings, drawing over 30,000 business visitors. Overall footfall, including exhibitors, crossed 50,000.

Buyers from 128 countries participated, including national procurement agencies from Cuba, the Philippines, Zambia, Palestine, Tajikistan, Maldives, Afghanistan, Mali, El Salvador, Libya, Fiji, Burkina Faso, Tunisia, Kenya, Mauritius, and Malawi. Discussions spanned pharmaceuticals, active pharmaceutical ingredients, formulations, therapeutics, and medical devices. The overall product mix discussed was approximately 39 percent therapeutics, 35.1 percent formulations, and 25.8 percent active pharmaceutical ingredients.

CDSCO officials outlined a move towards a more proportionate, risk-based regulatory framework, greater use of digital systems, and simpler compliance while maintaining safety, quality, and efficacy standards.

Pharmexcil Chairman Namit Joshi stated that the participation of buyers from 128 countries reflects continued interest in sourcing from and partnering with Indian pharmaceutical companies. He noted that the focus now is on helping the industry convert these discussions into sustained commercial relationships and build stronger access to newer geographies.

Why It Matters: This event demonstrates the global pharmaceutical industry's confidence in Indian manufacturers and opens new avenues for export growth.

Impact on Export Market: Potential business discussions worth $4.5–5 billion represent a significant opportunity for Indian pharmaceutical exporters.

Impact on Pharmaceutical Companies: Indian companies gained direct access to international buyers and procurement agencies from 128 countries.

₹1,600 Crore Approved for 41 Pharma and MedTech Innovation Projects

Publication Date: 30 September 2026

Under the first call of the Promotion of Research and Innovation in Pharma MedTech Sector, 41 projects were approved for around ₹1,600 crore in financial assistance. The approved projects are expected to catalyze an additional ₹3,020 crore of private investment, taking the total research and development investment across these projects to around ₹4,620 crore.

The approved portfolio spans the innovation value chain, covering novel drug discovery, clinical development, and innovative medical technologies. Of the 41 projects approved, 12 are at an early stage and 29 are at a later stage. Nineteen projects are being undertaken by startups and MSMEs, while 22 are being undertaken by large companies.

In terms of priority areas, 27 projects fall under New Medicines, five under Complex Generics and Biosimilars, and nine under Novel Medical Devices. The portfolio includes projects by companies and innovators such as Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology, and Bugworks Research.

Projects supported include an antibacterial targeting multidrug-resistant Gram-negative infections, an exosome-based regenerative therapy for corneal disease, an in-vivo CAR-T platform, patient-derived breast cancer organoids, a programmable RNA-targeting antiviral technology, portable plasmonic-PCR for point-of-care infection diagnosis, and a microfluidic platform for TB detection.

Why It Matters: This represents a significant shift from a predominantly volume-driven pharmaceutical model toward an innovation-led, technology-intensive model.

Impact on Pharmaceutical Companies: Companies receiving funding will accelerate research and development activities in priority areas.

Impact on Patients: New medicines, complex generics, and innovative medical devices will address unmet medical needs.

CDSCO Takes Action Against Misbranded and NSQ Rabies Vaccine

Publication Date: 7 September 2026

The Central Drugs Standard Control Organisation reported identification of a Not of Standard Quality vaccine misbranded as rabies vaccine Abhayrab, a brand manufactured and distributed by Indian Immunologicals Ltd. The regulator, in coordination with the Crime Branch of Delhi Police, conducted a search at an unlicensed premises in Delhi in April 2026 and seized the vaccine which was not manufactured by Indian Immunologicals Ltd.

The sample was declared as misbranded and NSQ by the Central Drugs Laboratory, Kasauli. Following this, the Drugs Controller General of India on August 27, 2026, requested all State Drugs Controllers to alert their inspectorate staff and maintain strict vigilance over the movement, distribution, and availability of the batch.

Indian Immunologicals Ltd stated that the vials examined are not a product manufactured by Human Biologicals Institute, the vaccine and human health division of the company. The company confirmed that every batch of Abhayrab is released for sale only after independent testing and batch-release certification by the government vaccine testing laboratory.

A total of four persons were arrested by the Delhi Police in connection with the case. It was also confirmed that no part of the batch concerned was exported to any other country.

Why It Matters: Rabies is an almost 100 percent fatal infection, and counterfeit or substandard vaccines pose a serious risk to patients.

Impact on Patients: Enhanced vigilance ensures that patients receive only genuine, quality-tested vaccines.

Impact on Pharmaceutical Companies: This action reinforces the importance of maintaining secure supply chains and protecting brand integrity.

Ghaziabad Company Stopped from Manufacturing Rabies Vaccine

Publication Date: 10 September 2026

Bio Med, a Ghaziabad-based pharmaceutical company, was issued a stop-production order after at least two batches of its anti-rabies vaccine, Sure Rab, failed the Bacterial Endotoxin Test, a critical quality-control procedure used to detect fever-causing bacterial toxins in injectable vaccines.

The Central Drugs Laboratory, Kasauli, under the CDSCO, declared both batches as Not of Standard Quality. One of the batches also failed on the parameter for bovine serum albumin, a major protein found in cow blood used during rabies vaccine manufacturing.

Following the test results, a joint inspection of Bio Med's manufacturing premises was carried out along with the Uttar Pradesh Food and Drug Administration. The company, established in 2002, was directed to completely stop the production of anti-rabies vaccines.

Bio Med is among five Indian manufacturers of anti-rabies vaccines. Other major players include Indian Immunologicals Limited, Bharat Biotech, Serum Institute of India, and Cadila.

Why It Matters: This action demonstrates the regulator's commitment to ensuring vaccine quality and patient safety.

Impact on Patients: Removal of substandard vaccines from the market protects patients from potential harm.

Impact on Pharmaceutical Companies: Manufacturers must maintain rigorous quality control standards to avoid regulatory action.

India Pharma Exports Diversify Beyond US as Shipments to Largest Market Decline

Publication Date: 18 September 2026

India is widening its pharmaceutical export base across Latin America, Africa, and Europe after shipments to the United States declined nearly 10 percent last year, according to Pharmexcil Chairman Namit Joshi. The decline in the US market resulted in an erosion of nearly $1 billion in exports, with shipments falling from around $10.5 billion to about $9.5 billion.

Despite the decline in India's biggest pharmaceutical export market, the country was able to record overall growth. The impact of weaker US shipments was mitigated to a large extent by growth in Brazil and other Latin American markets, along with some African countries, while Europe remained relatively stable.

India's pharmaceutical exports grew 6.8 percent during the April-June quarter to $8.1 billion from around $7.5 billion in the corresponding period last year. Joshi stated that the performance came despite global instability and challenges, demonstrating that India's supply chain is resilient.

Pharmexcil is focusing on widening India's export markets rather than remaining heavily dependent on a single country. Joshi noted that rather than depending on one country contributing 35 percent of exports, the market spread has improved.

Why It Matters: Export diversification reduces vulnerability to market-specific disruptions and strengthens India's position as a global pharmaceutical supplier.

Impact on Export Market: Growth in Latin America, Africa, and Europe offsets the decline in US shipments.

Impact on Pharmaceutical Companies: Companies with diversified export portfolios are better positioned to weather market fluctuations.

Alembic Pharmaceuticals Completes USFDA Inspection with Zero Observations

Publication Date: 11 September 2026

Alembic Pharmaceuticals successfully completed an unannounced onsite Bioequivalence inspection conducted by the United States Food and Drug Administration at the company's Bioequivalence Facility located in Vadodara, Gujarat. The inspection was conducted from August 31, 2026, to September 10, 2026, and concluded with no Form 483 observations.

This successful inspection demonstrates the company's commitment to maintaining high quality standards and regulatory compliance. A clean inspection with zero observations is a significant achievement for any pharmaceutical facility exporting to the US market.

Why It Matters: A clean USFDA inspection validates the quality systems and compliance standards at the facility.

Impact on Pharmaceutical Companies: This successful inspection strengthens Alembic's position as a reliable supplier to the US market.

Impact on Investors: Positive regulatory outcomes reduce compliance risk and support business continuity.

Apitoria Pharma Completes USFDA Inspection with One Procedural Observation

Publication Date: 15 September 2026

Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, completed a USFDA inspection at its API manufacturing facility in Telangana. The inspection was conducted from September 7 to September 15, 2026, and concluded with one observation, which the company described as procedural in nature.

The company stated that it will respond to the USFDA within the stipulated timeline. A single procedural observation is generally considered manageable, and the company's commitment to addressing it promptly reflects its focus on regulatory compliance.

Why It Matters: While any observation requires attention, a single procedural issue is significantly less concerning than quality or data integrity findings.

Impact on Pharmaceutical Companies: Prompt corrective action will help maintain the facility's compliance status.

Impact on Export Market: Continued US market access for API products from this facility.

India Initiates Anti-Dumping Investigation on Montelukast Sodium from China

Publication Date: 24 September 2026

The Indian government initiated an anti-dumping investigation into imports of Montelukast Sodium originating from or exported by China. The investigation was initiated by the Ministry of Commerce and Industry following an application by Morepen Laboratories Limited.

Montelukast Sodium is an active pharmaceutical ingredient used in the treatment of asthma and allergic conditions. The anti-dumping investigation follows standard trade remedy procedures to determine whether imports are being dumped at unfairly low prices and causing material injury to the domestic industry.

Why It Matters: This action reflects India's efforts to protect domestic API manufacturers from unfair trade practices.

Impact on Pharmaceutical Companies: Domestic manufacturers of Montelukast Sodium may benefit from protective measures if dumping is confirmed.

Impact on Export Market: Importers of Chinese Montelukast Sodium may face additional duties if the investigation concludes in favor of the domestic industry.

NATCO Pharma Receives In-Principle Approval for Rights Issue

Publication Date: 21 September 2026

NATCO Pharma received in-principle approval from the National Stock Exchange of India Limited and BSE Limited for a rights issue of fully paid-up equity shares of the company. The approval was granted on September 21, 2026.

A rights issue allows existing shareholders to purchase additional shares at a discounted price, typically used to raise capital for expansion, debt reduction, or other corporate purposes. The company will announce further details regarding the rights issue in due course.

Why It Matters: The rights issue provides the company with an opportunity to raise capital while giving existing shareholders the chance to increase their stake.

Impact on Investors: Existing shareholders will have the opportunity to participate in the rights issue.

Impact on Pharmaceutical Companies: The capital raised will support the company's growth initiatives.

Industry Summary

Raw Material Cost Crisis: The most significant challenge facing the pharmaceutical industry in September 2026 is the unprecedented surge in raw material and packaging material prices. APIs, solvents, excipients, and packaging materials have seen price increases of 30-300 percent, driven by geopolitical disruptions and supply chain bottlenecks. Industry bodies have warned that if costs cannot be recovered, medicine prices will inevitably rise, affecting public health and healthcare affordability. The industry is seeking government support through temporary price relaxations, freight subsidies, and GST relief on key inputs.

Innovation and Research Investment: September 2026 marked a significant milestone with the approval of ₹1,600 crore in funding for 41 pharmaceutical and medical technology innovation projects under the PRIP scheme. This represents a decisive shift toward an innovation-led pharmaceutical model, with projects spanning novel drug discovery, complex generics, biosimilars, and advanced medical devices.

Export Diversification: India's pharmaceutical exports showed resilience despite a nearly 10 percent decline in shipments to the United States. Growth in Latin America, Africa, and Europe helped offset the decline in the US market, demonstrating the benefits of export diversification. The iPHEX 2026 exhibition generated potential business discussions worth $4.5–5 billion, with buyers from 128 countries participating.

Regulatory Enforcement: The CDSCO took firm action against misbranded and substandard rabies vaccines during September. A counterfeit batch of Abhayrab was identified, and a Ghaziabad-based manufacturer was stopped from producing anti-rabies vaccines after quality failures. These actions demonstrate the regulator's commitment to patient safety.

USFDA Inspections: Alembic Pharmaceuticals successfully completed an unannounced USFDA inspection at its Bioequivalence Facility in Vadodara with zero observations. Apitoria Pharma, a subsidiary of Aurobindo Pharma, completed a USFDA inspection with one procedural observation.

Trade Actions: India initiated an anti-dumping investigation into imports of Montelukast Sodium from China, reflecting efforts to protect domestic API manufacturers.

Monthly Highlights: Top Pharma Headlines of September 2026

Raw material and packaging material prices surge, threatening pharma industry viability
iPHEX 2026 concludes with $4.5–5 billion in potential business discussions
₹1,600 crore approved for 41 pharma and MedTech innovation projects under PRIP
CDSCO takes action against misbranded and NSQ rabies vaccine Abhayrab
Ghaziabad company stopped from manufacturing rabies vaccine after quality failures
India pharma exports diversify beyond US as shipments to largest market decline
Alembic Pharmaceuticals completes USFDA inspection with zero observations
Apitoria Pharma completes USFDA inspection with one procedural observation
India initiates anti-dumping investigation on Montelukast Sodium from China
NATCO Pharma receives in-principle approval for rights issue
Pharmexcil targets $1.4 billion in export opportunities through iPHEX 2026
CDSCO outlines move towards risk-based regulatory framework at iPHEX
128 countries participate in iPHEX 2026 with national procurement agencies from 15 countries

FAQ Section

What are the top pharmaceutical trends for 2026?

Major trends include increased government investment in pharmaceutical research and innovation through the PRIP scheme, export diversification beyond traditional markets, stricter regulatory enforcement on vaccine quality, and a growing raw material cost crisis that threatens industry viability and medicine affordability.

What are the latest pharma news updates this month?

September 2026 key updates include the approval of ₹1,600 crore for 41 innovation projects, iPHEX 2026 generating $4.5–5 billion in potential business discussions, CDSCO action against misbranded rabies vaccines, India's export diversification strategy, and the escalating raw material cost crisis affecting pharmaceutical manufacturers.

What happened in the pharmaceutical industry during September 2026?

September 2026 was marked by significant government investment in pharmaceutical innovation, a major international exhibition generating billions in business opportunities, regulatory action against substandard vaccines, continued export growth through market diversification, and a deepening raw material cost crisis that is squeezing industry margins and threatening medicine affordability.

Which pharmaceutical companies made major announcements this month?

Companies involved in PRIP funding include Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, and Mankind Pharma. Alembic Pharmaceuticals completed a clean USFDA inspection, and NATCO Pharma received approval for a rights issue.

Which medicines received important approvals in September 2026?

The PRIP scheme approved funding for 27 new medicine projects, five complex generics and biosimilars projects, and nine novel medical device projects.

What are the biggest pharma industry updates in India?

The biggest updates include the ₹1,600 crore PRIP funding approval, iPHEX 2026 generating $4.5–5 billion in potential business, CDSCO's action against counterfeit rabies vaccines, and the escalating raw material cost crisis that threatens industry viability and medicine affordability.

Where can I find all monthly pharma industry news?

Visit GreenCrossIndia.com/blog for regular Monthly Pharma News Updates.

Why should healthcare professionals follow monthly pharma news?

Following monthly pharma news helps healthcare professionals stay informed about new drug approvals, regulatory changes, safety alerts, and industry trends. September 2026 updates include important information about vaccine quality actions, the raw material cost crisis, and innovation funding.

What are the latest regulatory updates in India's pharmaceutical industry?

The CDSCO took action against misbranded and NSQ rabies vaccines, requested states to maintain vigilance, and outlined a move towards a risk-based regulatory framework at iPHEX 2026. The regulator also approved funding for 41 innovation projects under the PRIP scheme.

What should pharma distributors and healthcare professionals know from this month's updates?

Pharma distributors should be aware of the CDSCO's vigilance alert regarding counterfeit rabies vaccines and ensure they source products only through authorized channels. They should also note the raw material cost crisis, which may lead to higher medicine prices in the coming months. The PRIP funding approvals signal growing opportunities in pharmaceutical innovation and research.

Conclusion

September 2026 proved to be a month of both remarkable achievement and serious challenge for the Indian pharmaceutical industry. On one hand, the approval of ₹1,600 crore for 41 innovation projects under the PRIP scheme represents a decisive shift toward research-driven pharmaceutical development. The iPHEX 2026 exhibition demonstrated India's growing stature as a global pharmaceutical hub, generating potential business discussions worth $4.5–5 billion with participation from buyers across 128 countries. India's export diversification strategy showed resilience, with growth in Latin America, Africa, and Europe helping offset a nearly 10 percent decline in shipments to the United States.

On the other hand, the raw material and packaging material cost crisis has reached alarming proportions. Prices of APIs, solvents, excipients, and packaging materials have surged by 30-300 percent, driven by geopolitical disruptions and supply chain bottlenecks. MSME pharmaceutical manufacturers are bearing the brunt of this crisis, with many operating on thin margins and limited capacity to absorb cost increases. The industry has warned that if costs cannot be recovered, medicine prices will inevitably rise, affecting public health and healthcare affordability.

Regulatory authorities demonstrated their commitment to patient safety through decisive action against misbranded and substandard rabies vaccines. The CDSCO's vigilance alert and the stop-production order against a Ghaziabad manufacturer send a clear message that quality violations will not be tolerated.

The Indian pharmaceutical industry stands at a critical juncture. The government's support through innovation funding, export promotion, and regulatory modernization is commendable. However, the industry urgently needs relief from the raw material cost crisis to maintain both its viability and its ability to provide affordable medicines to patients. Temporary price relaxations, freight subsidies, GST relief on key inputs, and faster processing of refunds are essential measures that can help the industry weather this storm.

As India continues its journey toward becoming a global pharmaceutical innovation hub, the balance between industry viability and patient affordability will remain a central challenge. Government support, industry resilience, and regulatory excellence will all be essential in the months ahead.

Disclaimer

The information shared in this article is based on publicly available and verified pharmaceutical industry news published during 01 September 2026 to 30 September 2026. The content is prepared only for educational and informational purposes. While every effort has been made to ensure accuracy, readers are advised to verify important announcements with the respective pharmaceutical companies or regulatory authorities before making any business or professional decisions.